Efficacy of single vs. multiple botulinum toxin type A injections for trigeminal neuralgia.

Frontiers in neurology 2025 Vol.16() p. 1570447

Xu YY, Guo CW, Chen HJ, Bao JL, Li Y, Ma SY, Zhang QL, Liu J, Luo WF

관련 도메인

Abstract

[BACKGROUND] The effectiveness of Botulinum toxin type A (BTX-A) has been established in trigeminal neuralgia (TN). This study aimed to assess the therapeutic efficacy and safety of BTX-A injection within a group of TN patients who have chosen to continue BTX-A therapy.

[METHODS] This was a retrospective medical record-review study. Demographic and clinical features and severity and frequency of pain before and 4 weeks after the BTX-A administration were extracted from the patient files. BTX-A was injected into the painful area subcutaneously and/or submucosally. BTX-A injections were performed by the same physician using the same methods. Pain severity was assessed using the visual analog scale (VAS). The patient's overall response to treatment was assessed using the Patient Global Impression of Change (PGIC). Patients were divided into two groups, single-treatment (TN-S) group and multiple-treatment (TN-M) group, according to the numbers of treatment.

[RESULTS] Thirty patients were included in this study. We classified 16 (53.33%) as TN-S group and 14 (46.67%) as TN-M group. The median VAS score of all patients was 8 (6.75, 10) before the first treatment and 3 (2, 6.25) after the first treatment ( < 0.001). In the TN-M group, median of the difference of VAS before and after treatment of the first and the last treatment were 7 (5, 8) and 5 (2, 7.25), respectively, indicating a significantly better effect for the first treatment compared with the last treatment ( = 0.024). However, this difference in PGIC distributions between the two treatments was not significant ( = 0.070).

[CONCLUSION] In summary, BTX-A treatment was effective in TN. Elderly patients and patients with good response to the first treatment were more likely to choose to continue BTX-A multiple-treatments. BTX-A remains effective within a group of TN patients who have chosen to continue BTX-A therapy, but the efficacy decreases to a certain extent after multiple treatments.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 botulinum toxin 보툴리눔독소 주사 dict 2
해부 trigeminal scispacy 1
해부 trigeminal neuralgia scispacy 1
약물 [BACKGROUND] scispacy 1
약물 BTX-A → Botulinum toxin type A scispacy 1
질환 trigeminal neuralgia C0040997
Trigeminal Neuralgia
scispacy 1
질환 pain C0030193
Pain
scispacy 1
질환 TN patients scispacy 1
질환 PGIC → Patient Global Impression of Change scispacy 1
기타 Botulinum toxin type A scispacy 1
기타 patient scispacy 1
기타 Patients scispacy 1

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문